Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

NCT02877550 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Venetoclax

Sponsor

Swiss Cancer Institute